Viking Therapeutics, Inc. (VKTX)
| Market Cap | 4.36B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -237.39M |
| Shares Out | 113.04M |
| EPS (ttm) | -2.12 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,745,898 |
| Open | 38.34 |
| Previous Close | 38.57 |
| Day's Range | 38.05 - 39.48 |
| 52-Week Range | 18.92 - 52.58 |
| Beta | 0.64 |
| Analysts | Strong Buy |
| Price Target | 87.07 (+125.86%) |
| Earnings Date | Oct 22, 2025 |
About VKTX
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for VKTX stock is "Strong Buy." The 12-month stock price target is $87.07, which is an increase of 125.86% from the latest price.
News
Prediction: This Undervalued Stock Could Compete With Novo Nordisk by 2029
Viking Therapeutics could enter the weight loss market by 2029. The company's leading candidate looks very promising.
Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference
SAN DIEGO , Nov. 25, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic an...
2 Healthcare Stocks for Beginner Investors With a 20-Year Time Horizon
If you want to invest in top healthcare stocks, both of these are worth consideration. Pfizer is moving past the pandemic era, and tremendous growth could be ahead.
3 Weight-Loss Drug Stocks To Consider For 2026
The global weight loss drug market, perhaps ironically, is growing like gangbusters these days. Globally, it's set to expand from $15 billion in 2024 to $150 billion by 2035, according to Morgan Stanl...
3 Mid-Cap Growth Stocks That Have Mammoth Long-Term Potential
Mid-cap stocks can come with risks, but also a ton of upside in the long run. The stocks listed here offer exciting growth opportunities across multiple industries.
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
Eli Lilly has advanced in the triple-digits over three years, thanks to its weight loss drug portfolio. The following two biotech companies, due to the potential of their late-stage candidates, also c...
Viking Therapeutics, Inc. (VKTX) Presents at Jefferies London Healthcare Conference 2025 Transcript
Viking Therapeutics, Inc. ( VKTX) Jefferies London Healthcare Conference 2025 November 19, 2025 3:00 AM EST Company Participants Brian Lian - President, CEO & Director Conference Call Participants Ji...
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735
78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity Enrollment Completed Ahead of Schedule and Above Target Size, Indicating Strong Interest in VK2735 SAN DIEGO , Nov. 19, 2025 /PRNews...
5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity?
Exited entire position: down 189,593 shares, a net position change of $5.02 million No remaining shares held; post-trade stake is zero The position previously accounted for approximately 1.9% of the f...
2 No-Brainer Healthcare Stocks to Buy Now
Pfizer's acquisition of obesity drugmaker Metsera positions the pharmaceutical giant to compete in a market expected to reach $130 billion by 2030. Viking Therapeutics has both injectable and oral ver...
2 Monster Stocks in the Making
Viking Therapeutics is developing innovative medicines in a fast-growing area. Axsome Therapeutics is generating strong sales, and solid regulatory progress could improve things.
Is There a Future for Viking Therapeutics?
Viking has initiated an exciting new phase 1 study combining an oral and subcutaneous formulation of a weight loss drug. The phase 1 trial results are expected next year, with the Phase 3 (subcutaneou...
Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025
VENTURE Study Exploratory Analysis Shows VK2735 Improved Cardiometabolic Parameters After 13 Weeks; Reducing Prediabetes and Metabolic Syndrome SAN DIEGO , Nov. 6, 2025 /PRNewswire/ -- Viking Therapeu...
Druckenmiller's Viking Trade Just Hit A Golden Cross — And A Sweet 36% Gain
Stanley Druckenmiller 's Viking Therapeutics Inc (NASDAQ:VKTX) bet is starting to look like a classic Druckenmiller move — quietly bold, impeccably timed, and now technically validated. The billionair...
Here's Why Shares in Viking Therapeutics Shot Higher in October
Takeover speculation is rife in the industry, particularly with companies with promising obesity drug pipelines. Management reassured investors that there could be substantial value in its lead drug c...
Billionaire Stanley Druckenmiller Dropped Nvidia and Palantir Stock and Is Piling into 2 Stocks Set to Win in One of the Decade's Hottest Growth Markets.
Stanley Druckenmiller has a fantastic investing track record, delivering a double-digit average annual return over time. The billionaire sold artificial intelligence (AI) leaders Nvidia and Palantir -...
Viking Therapeutics to Participate at Upcoming Investor Conferences
SAN DIEGO , Nov. 4, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and...
Prediction: The Next Eli Lilly Might Already Be Trading Under $50
Viking Therapeutics is developing a weight loss medicine in the same general class as Eli Lilly's tirzepatide. The mid-cap biotech is exploring options for a potential quadruple agonist therapy.
Should You Buy Viking Therapeutics Before Nov. 5?
Viking Therapeutics aims to enter one of today's biggest healthcare growth areas: the weight loss drug market. The company is evaluating an injectable candidate in phase 3 studies and an oral candidat...
3 Promising Growth Stocks That Are Down Around 60% From Their Highs
Viking Therapeutics, Cava Group, and Figma are three stocks that have been struggling in recent months. These businesses possess some exciting growth potential, which could make them ideal long-term i...
Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2025
Poster Presentation on VENTURE Study Results Evaluating Impact of VK2735 on Prediabetes and Cardiometabolic Status Additional Poster Presentations Scheduled for American Heart Association Scientific S...
Here's Why This Obesity Drug Company's Share Price Soared Today
The company's lead drug candidate is in a phase 3 trial, and enrollment is progressing well. The drug is also being tested in oral formulation, and there's plenty of value in Viking's pipeline.
Viking Therapeutics Q3 Earnings: What We Learned (And Why We Should Keep Faith)
Viking Therapeutics, Inc. remains a Buy as VK2735 is arguably the leading GLP-1 obesity drug candidate outside of Eli Lilly and Novo Nordisk's pipelines. VKTX's pivotal VANQUISH Phase 3 injectable stu...
Viking Therapeutics: The Prime Target In The Obesity Gold Rush
Viking Therapeutics, Inc. is a clinical-stage biotech focused on metabolic and endocrine therapies, highlighted by its promising VK2735 obesity drug. VKTX's pipeline includes late-stage GLP-1/GIP agon...
Viking Therapeutics, Inc. (VKTX) Q3 2025 Earnings Call Transcript
Viking Therapeutics, Inc. (NASDAQ:VKTX) Q3 2025 Earnings Call October 22, 2025 4:30 PM EDT Company Participants Brian Lian - President, CEO & Director Gregory Zante - Chief Financial Officer Conferen...